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Abstract
Background: Vitamin A may have some influence on the immune system, but the role in allergy
modulation is still unclear.
Objective: To clarify whether high levels of retinoic acid (RA) affects allergic response in vivo, we
used a murine experimental model of airway allergic disease.
Methods:  Ovalbumin (OVA)-immunization/OVA-challenge (OVA/OVA) and house dust mite
(HDM)-immunization/HDM-challenge (HDM/HDM) experimental murine models of allergic airway
disease, using C57Bl.10/Q groups of mice (n = 10) treated subcutaneously with different
concentrations of all-trans RA (0, 50, 500 and 2,500 ug) every 2-days were used to assess the
allergic immune response.
Results: Levels of total and specific-IgE in sera were increased in all groups of RA treated OVA/
OVA and HDM/HDM mice. Percentage and total amount of recruited eosinophil in airways by
bronchoalveolar lavage fluid (BALF) were significantly enhanced in groups treated with 50, 500 and
2,500 ug of RA compared to non-treated mice. However, the group of mice treated with 2,500 ug
had less eosinophil recruitment than the other two groups (50 and 500 ug). In parallel, levels of IL-
5 and total IgE in BALF were also significantly diminished in the group treated with 2,500 ug
compared to the other 2 groups (50 and 500 ug). Finally, total lung resistance was decreased in
group treated with 2,500 ug compared to non-treated mice.
Conclusion: Our results suggest that retinoic acid directly enhances allergic response in vivo, but
in higher doses may produce of immune suppression.
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Introduction
The incidence of atopic diseases can be considered epi-
demic [1], although sensitization rate is invariant, the
prevalence has peaked in some regions [2] and an increase
has been recorded in several developing countries [3].
Some epidemiological studies have found that the highest
prevalence for asthma symptoms was mainly in Western
countries. These findings have not only raised the possi-
bility of genetic factors but also mainly that environmen-
tal factors relating to living conditions in these countries
are also important [4], such as westernized life style in
which air pollution and the consumption of lots of addi-
tives/preservatives can be involved. The presence of
enriched foodstuffs with several elements, such as fat-sol-
uble vitamins, is one of the differences between develop-
ing and developed countries. Although the benefit has no
doubt, several studies have described the possible influ-
ence on development of allergic diseases.
The influence of fat-soluble vitamins, such as vitamin D or
A, on the immune system have been recently studied [5].
Calcitriol, active metabolite of vitamin D, acts in the
immune system through its specific intracellular receptor
(VDR) and has been recently shown to have influence in
experimental murine models of multiple sclerosis [6], dia-
betes [7], arthritis [8] and asthma [9] with a shift in Th1/
Th2 balance.
Similarly, action of vitamin A, so called retinol, is medi-
ated over antigen presenting cells (APC) through specific
intracellular retinoid acid receptors (RAR) [10] and retin-
oid × receptors (RXR)[11], which are present in the
immune cells [12]. It has been recently shown, the effect
of retinoic acid in T cells, with a decrease of the T-helper 1
(Th1) immune response and an increase of Th2 immune
response in vitro [10] and in vivo [13]. The vitamin A has
shown to suppress [14] and prevent [15] the induction in
vivo  of experimental autoimmune encephalomyelitis
(EAE), an experimental model of a Th1 disease. And it has
been recently suggested that RAR antagonists may be use-
ful as agents to treat rheumatoid arthritis showing the
clinical potential of RAR antagonists in arthritis [16].
Retinoic acid also reduces autoimmune renal injury and
increases survival in mice [17]. Finally, some epidemio-
logical studies either in US [18] and in Sweden [19] have
shown that vitamin A supplementation within first
months of life has been associated with increased risk of
asthma and postulated with a Th2 skew.
Materials and methods
Animals, immunization and treatment
Groups of pathogen-free female C57BL/10 mice, weight
17-21 g, age 6-7 weeks, were used in the experiments.
Mice were fed a standard chow diet [20] containing nor-
mal range of vitA/g diet (4 IU/g), and kept in a climate-
controlled environment with 12-h cycles of light/dark and
sound. All animal care and experimentation were con-
ducted at the Animal Unit of Medical Inflammation Research
(Lund University, Sweden). Additional experiments were
performed at Universidad de La Laguna and Hospital Gen-
eral Universitario Gregorio Marañon (Spain). All experi-
ments were approved by local Institutional Animal Care
and Use Committee in accordance with international pro-
tocols of caring animals.
Groups of mice were immunized by intraperitoneal injec-
tions of 5-μg Dermatophagoydes pteronyssinus (HDM, Alk-
Abelló, Spain) complexed with 2-mg aluminum potas-
sium sulphate (Alum, Sigma Chemical Co., St Louis, Mo)
on days 0 (D0) and 4 (D4). On D14 and D15, mice were
challenged with 5-μg HDM delivered intranasally [21]
after slight anesthesia. Additional experiments were per-
formed with chicken egg albumin (OVA, Sigma) plus
Alum as described previously [22]. On D16, 24 h after the
last allergen exposure, the mice were assessed for lung
allergic inflammatory response.
Three days before immunization (D-3), different groups
of mice received a subcutaneous injection of 50 μL of PBS-
Tween 20 buffer containing 0, 50, 500 or 2,500 μg of all-
cis-transretinoic acid (ATRA, Sigma). Subsequently, the
injections were also given every second day until the end
of experiment as follows: D-1, 1, 3, 5, 7, 9, 11, 13 and 15
[20].
Local immune response
On day 16 mice bronchoalveolar lavage fluid (BALF) was
recruited as described before [22,23]. Mice were deeply
anesthetized and trachea was cannulated to perform BALF
with 1-ml of PBS buffer. Then, when cells were attached to
slides by cytospin and stained, cell counts were deter-
mined. The number of recruited cells in pulmonary air-
ways was counted after staining (Diff-Quick, Sigma) 24 h
after last challenge. Differential of cells were determined
after counting at least 400 cells per slide in a blinded fash-
ion. Single supernatants were used to determine IgE levels
and cytokine content by enzyme-immunoassays as
described before [22] using monoclonal Ab (anti-IL-4,
anti-IL-5, anti-IL-13, anti-IFN-γ (BD Pharmingen, San
Diego, CA, USA). Standard curves were constructed with
purified IL-4, IL-5, IL-13 and IFN-γ.
For RT-PCR analysis, total RNA was extracted with RNAzol
B (Biotech Laboratories, Friendswood, TX) from homoge-
nized lung cells from right lung, and the oligo (dT)-
primed cDNA was prepared with the First-Strand cDNA
Synthesis Kit (Amersham Pharmacia Biotech, Bucking-
hamshire, UK) [24]. To amplify cytokine messages, the
samples were incubated as described elsewhere. All PCR
reactions were controlled by β-actin expression, and PCRNutrition & Metabolism 2009, 6:44 http://www.nutritionandmetabolism.com/content/6/1/44
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primers as described before [25]; (IL5-6F:5'-AGCACAGT-
GGTGAAAGAGACCTT; IL5-6R:5'-TCCAATGCATAGCT-
GGTGATTT) were used as described before [26]. A
mathematical model published before was applied [27]
and the relative expression ratio was calculated from the
real-time PCR efficiencies and the crossing point devia-
tion of an unknown sample versus a control Ct IL-5 repre-
sents cycles when IL-5 expression is augmented; Ct Ract
represents cycles when R actine expression is augmented
(control); Ct IL-5/Ct Ract represents ratio. Control levels
were included in the model to standardise each reaction
run with respect to RNA integrity, sample loading and
inter-PCR variations. High accuracy and reproducibility
(<2.5% variation) were reached in LightCycler PCR
(Roche, Mannheim, Germany) using the established
mathematical model [27].
Lung responsiveness
In additional experiments, 24 hours after the trans-nasal
challenge with OVA, airway responsiveness was assessed.
Four individual whole-body plethysmograph chambers,
obtained from Buxco (Troy, NY, USA), were used as
described elsewhere [28]. In this system, unrestrained,
spontaneously breathing mice are placed into the cham-
bers. The pressure differences between these and their
respective reference chambers are recorded and then the
enhanced pause (Penh) calculated. Penh is a dimension-
less value that represents a function of the proportion of
maximal expiratory to maximal inspiratory box pressure
signals and the timing of expiration. Penh was used to
monitor airway responsiveness in this study because it
closely correlates to pulmonary resistance measured by
conventional ventilated two-chamber plethysmography
in mice [28]. Mice were exposed for 2 min to nebulized
PBS [29] and subsequently to increasing concentrations of
nebulized metacholine (Mch) (Sigma) in PBS using an
aerosonic ultrasonic nebulizer (DeVilbiss, PA, USA). After
each nebulization, three minutes recordings were taken.
Penh measurements were averaged and are expressed for
each Mch concentration as the percentage of baseline
Penh values following PBS exposure. Three-min record-
ings of noninvasive measurement of airway responsive-
ness in allergic mice after each nebulization were assessed
[30].
Systemic immune response
Mice were bled at the time of sacrifice. Total IgE levels in
sera and BALF were determined by a sandwich ELISA (BD
Pharmingen). OVA-specific IgE levels were measured as
described previously [22].
Spleens were dissected at the time of sacrifice and spleno-
cytes were prepared, supplemented and cultured as
described before to measured specific cell proliferation
[31]. Single cell suspensions from each mouse were pre-
pared with Dulbecco's MEM with glutamax I (GIBCO
BRL, Life Technologies), supplemented with 10% heat-
inactivated FCS, 10 mmol/l HEPES, 50 mmol/l β-mercap-
toethanol, 100 U/ml penicillin G, and 100 μg/ml strepto-
mycin as culture medium. Cells were incubated (5 × 106/
ml) in triplicates at 37°C and 5% CO2 in a humidified
incubator. Medium, concavalin A as unspecific stimula-
tion or OVA (111 μM) [22] as specific stimulation were
separately added to the cultures. 54 hours later, 5 μL of
3H-thymidine (100 μCi/ml) were added to each well
before harvesting, and its incorporation was measured 18
h later in a beta-scintillation counter [20].
Statistic analysis
The significance of changes was evaluated using Mann-
Whitney U test. Significance was assumed at p values ≤
0.05.
Results
Cell profile in airways after treatment with all-
transretinoic acid has dose-dependent effect
To determine whether administration of different doses of
ATRA during all protocol could have any influence in the
development of allergic airway phenotype, BALF was col-
lected in every mouse. Total cell count was not signifi-
cantly affected by doses of 50 and 500 ug ATRA treatments
in the murine allergic model. Only when 2,500 ug of RA
was administered to mice, the number of recruited cells
was affected (table 1). However, the cell profile was differ-
ent depending on doses of treatment. After treatment with
50 ug ATRA every second day during the protocol, mice
had a different profile of recruited cells, with significantly
higher percentage of eosinophils (47,8% compared to
39,9% in non-treated) and lymphocytes and less macro-
phages and neutrophils in airways than HDM/sensitized-
HDM-challenge mice treated with control buffer during
the protocol (table 1). The percentage of eosinophils was
almost 50% in group treated with 500 ug and finally, it
was reduced to 11% in group treated with 2,500 ug every
second day. Similar differences were obtained when we
performed immunization and challenge using OVA (Fig-
ure 1).
Th2 cytokine induction and total IgE in airways by all 
transretinoic acid
Then, we studied the results of Th2 cytokines affected by
the minimal dose of RA treatment. Supernatants of BALF
were thawed and used to determine the airway cytokine
and IgE levels contents. We observed that the levels of IL-
4 production (Figure 2a) in BALF were enhanced upon 50,
500 or 2,500 ug of ATRA treatment (50 ug; mean: 67 ng/
ml; 500 ug: 71 ng/ml; 2,500 ug: 59 ng/ml) compared to
control buffer treated allergic mice (0 ug; mean: 44 ng/ml;
p < 0,05 n = 8 mice per group).Nutrition & Metabolism 2009, 6:44 http://www.nutritionandmetabolism.com/content/6/1/44
Page 4 of 11
(page number not for citation purposes)
Cell profile in BALF in OVA-immunized/OVA-challenged mice Figure 1
Cell profile in BALF in OVA-immunized/OVA-challenged mice. Individual BALF were collected 24 h after the last 
challenge from each group (n = 8/group) and cells were attached to slides, stained with histochemistry staining for eosinophils 
and, at least 400 cells, counted in a blind manner. Data are given as mean ± SEM, *p < 0.05 vs. non-treated group. † P < 0.05 vs 
2,500 treated group.
Table 1: Profile of recruited cells from airways by BALF
Treatment Total cells Eosinophils Monocytes Lymphocytes Neutrophils
PBS 240 ± 38§ 3 ± 1§ 201 ± 18 8 ± 5§ 10 ± 7
Dpt+Vit A 50 612 ± 36 293 ± 28 198 ± 24 86 ± 15 34 ± 8
Dpt+Vit A 500 624 ± 59 312 ± 29 199 ± 22 82 ± 12 29 ± 7
Dpt+Vit A 2500 428 ± 46 46 ± 35* 284 ± 34 79 ± 11 19 ± 7
Cells from BALF of house dust mite-sensitized and house dust mite challenge mice treated with ATRA or control buffer during the entire protocol. 
§p < 0.05 compared to groups treated with 50 and 500 of ATRA; * p < 0.05 compared to groups treated with 50 and 500 of ATRA.Nutrition & Metabolism 2009, 6:44 http://www.nutritionandmetabolism.com/content/6/1/44
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IL-5 (Figure 2B) was also enhanced in groups treated with
50 and 500 ug ATRA (50 ug; mean: 151 ng/ml; 500 ug:
149 ng/ml) compared to non-treated mice (0 ug; mean:
98 ng/ml). However, the group of mice treated with 2,500
ug (2,500 ug; mean: 106 ng/ml) have lower levels of IL-5
than the other 2 groups (50 and 500 ug; p < 0,05) but
were not significantly different from non-treated mice.
IFN-gamma production in airways of mice was similar in
all groups (0 ug; mean: 228 ng/ml; 50 ug: 231 ng/ml; 500
ug: 252 ng/ml; 2,500 ug: 221 ng/ml) compared to non-
allergic control mice (mean: 148 ng/ml) (Figure 2c).
Similarly to IL-4 results, levels of total IgE in airways of
mice were enhanced upon treatment in all treated groups
(50 ug; mean: 84 ng/ml; 500 ug: 82 ng/ml; 2,500 ug: 77
ng/ml) compared to non-treated allergic mice (0 ug;
mean: 57 ng/ml) (Figure 2d).
Total and specific IgE are increased after treatment with 
all-transretinoic acid
Next, we investigated whether treatment with ATRA every
second day had an influence on the IgE response at the
end of protocol. We found that treatment with ATRA
resulted in significant enhancement of total IgE in all
groups (50 ug; mean: 3,020 ng/ml; 500 ug: 3,189 ng/ml;
BALF cytokine levels Figure 2
BALF cytokine levels. Concentration of protein determined by ELISA in immunized and challenged mice 24 h after last 
intranasal allergen challenge (n = 8/group). (A) IL-4 levels were significantly augmented in all treated groups compared to non-
treated group. (B) IL-5 levels were significantly augmented in groups treated with 50 and 500 ug of VA every second day com-
pared to non-treated group. However, levels in group of mice treated with 2,500 ug every second day, were reduced com-
pared to previous treated groups. There was not significant difference between 2,500 group and non-treated group. (C) IFN-γ 
in airways was not modified in treated mice. (D) Total IgE content in airways was also significantly increased after treatment 
with RA in all groups compared to non-treated mice. Data are given as mean ± SEM, *P < 0.05 vs. non-treated group.Nutrition & Metabolism 2009, 6:44 http://www.nutritionandmetabolism.com/content/6/1/44
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2,500 ug: 2,897 ng/ml) compared with non-treated group
(0 ug; mean: 2,149 ng/ml; Figure 3a). Specific IgE was also
increased by ATRA treatment (50 ug; mean: 603 ng/ml;
500 ug: 591 ng/ml; 2,500 ug: 578 ng/ml) compared with
non-treated mice (0 ug; mean: 399 ng/ml; Figure 3b).
Specific spleen cell proliferation was not affected by in 
vivo treatment with all-trans retinoic acid
We were interested to investigate how the dose of ATRA
affects the systemic specific T cell proliferation. After lysis
of RBC, single cell suspensions of splenocytes from each
mouse treated with ATRA were cultured in triplicates in
absence or presence of OVA. Measurement by a beta-scin-
tillation counter showed that antigen-specific in vitro cell
proliferation was not affected by in vivo treatment of mice
with 50 ug of ATRA every second day (Figure 4).
Treatment with highest dose of retinoic acid abolished 
airway hyperresponsiveness and downregulated 
expression of IL-5
Since cell profile in airway resulted in amelioration of
eosinophils and levels of IL-5 in airways when highest
doses of ATRA (2,500 ug every second day) were applied
in mice, we then were interested in investigating if studies
of airway function in vivo was affected. Additional experi-
ments were performed using the same protocol -OVA/
OVA- and 24 h after the last intranasal challenge with
OVA, ATRA treated mice showed a significant 2 to 3-fold
decrease of the airway response to metacholine using
whole-body plethysmography, when compared to the
untreated mice, as demonstrated by a progressive decrease
in P-enh values (Figure 5). Significant enhanced pause (P-
enh) was obtained at 24, 48 and 96 mg/mL of Mch inha-
lation. This result confirmed that treatment with the high-
Levels of total and specific IgE Figure 3
Levels of total and specific IgE. Levels were determined by sandwich ELISA in individual sera from immunized and chal-
lenged mice (n = 8/group) A) Total IgE levels showed increased levels in groups treated with ATRA compared to control mice 
received PBS alone. Significant differences were observed between treated and non-treated groups.Nutrition & Metabolism 2009, 6:44 http://www.nutritionandmetabolism.com/content/6/1/44
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est dose of ATRA every second day is enough to suppress
not only eosinophil recruitment in airways but also func-
tional effects on the airways.
In additional experiments, when the highest doses of
ATRA every second day were applied in mice, RT-PCR
analysis of homogenized lung parenchyma cells was also
done. After total RNA was extracted, the oligo (dT)-
primed cDNA was prepared. For qualitative assessment,
the PCR products were analyzed on 5% acrylamide gels
stained with ethidium bromide. As the figure 6 shows,
bands of IL-5 were more intense in mice treated with
2,500 ug of ATRA every second day compared to non-
treated mice. In quantitative analysis of IL-5, using the
Light Cycler quantitative PCR system (Roche, Mannheim,
Germany), results shows that there is a significant reduc-
tion of IL-5 expression in lung parenchyma of non-treated
allergic mice compared to mice treated with the highest
dose of ATRA every second day.
Discussion
Fat-soluble vitamins, such as vitamin D or A, are common
food additives with some influence on immune system.
The active metabolite of vitamin D, calcitriol, has been
shown to prevent the induction of experimental models
of autoimmune diseases and could influence the develop-
ment of a sustained Th2 response [9], leading to an
increasing prevalence of allergy.
Similarly, action of vitamin A, so called retinol, is medi-
ated over antigen presenting cells (APC) through specific
intracellular receptors (RAR, RXR) [10,11], which are
present in the immune cells. It has been recently shown
that the effect of retinoic acid in T cells [32] might produce
a decrease of the Th1 immune response [12] and an
increase of Th2 immune response in vitro [10]. Vitamin A
in the body is acquired from diet as preformed vitamin A
(mainly retinyl ester form) but also less amount of retinol
or retinoic acid [33]. Vitamin A is also acquired as dietary
pro-vitamin A carotenoids, which are absorbed by the
mucosal cells and are converted to retynaldehyde. Upon
Ex-vivo proliferation assays Figure 4
Ex-vivo proliferation assays. Splenocytes from individual treated and non-treated mice (n = 5/group) were harvested on day 
17 after immunization and challenge and cultured in triplicates in 96-well flat-bottomed plates at 37°C, 5% CO2 and stimulated 
in vitro in absence or presence of OVA (111 μM). 3H-thymidine (100 μCi/ml) was added to cultures 2 days later and after 18 hr 
proliferation was measured by a beta-scintillation counter. No differences were observed between treated and non-treated 
groups of mice.Nutrition & Metabolism 2009, 6:44 http://www.nutritionandmetabolism.com/content/6/1/44
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reduction to retinol, this is indistinguishable from other
forms coming from diet. For biological activity, retinol
must be oxidized to retinaldehyde and, subsequently to
retinoic acid [33]. In the present work, we used all-trans
retinoic acid by subcutaneous administration trying to
avoid some gastrointestinal interference in absorption of
vitamin A, and having of stable levels of retinoic acid in
blood. Retinoic acid has an important role in embryo
development (hindbrain and associated neural crest) with
mid-gestation interruption in retinoic total deficiency
[33]. Thus, the goal of our model was not to be deficient
in vitamin A in control mice, since RA deficiency is rare in
western countries.
Our results show that treatment with some extra-supple-
mentation of ATRA produces an up-regulation of IgE in
serum. It is known that the balance between Th1 and Th2
cells is in part controlled by Vitamin A, which inhibits IL-
12 synthesis through binding to retinoid receptors,
thereby favouring a Th2 response [12]. Other authors
have shown that blocking the RXR subunit of retinoid
receptors augmented the production of IL-12 by activated
monocytes and inhibited the development of Th2 cells in
vitro. Furthermore, in a mouse model of allergic asthma,
treatment with an RXR antagonist decreased the antigen-
specific Th2 response leading to reduced serum IgE levels
and strongly decreased lung eosinophilia after antigen
challenge. Therefore, retinoid receptor antagonists hold
promises for the treatment of Th2-mediated diseases
[34,35]. Furthermore, in a prospective birth cohort of
4089 newborn infants followed for 4 years using parental
questionnaires, children supplemented with vitamins A
and D in water-soluble form during the first year of life
had an almost 2-fold increased risk of asthma and sensiti-
zation to common food and airborne allergens at age 4
years compared with those receiving vitamins in peanut
oil, suggesting that supplementation of vitamins A and D
in water-soluble form seemed to increase the risk of aller-
gic disease [19].
Previously, some authors have shown that ATRA inhibits
IgE synthesis from anti-CD40 plus IL-4 stimulated human
B lymphocytes in in vitro experiments. Furthermore,
retinoic acid inhibited CD40 plus IL-4 mediated-IgE pro-
Determination of airway hyperresponsiveness Figure 5
Determination of airway hyperresponsiveness. Pulmonary function test were performed in sensitized and transnasally 
challenged mice. Mice were exposed to increasing doses of inhaled methacholine (Mch) and Penh values were registered. Aller-
gic mice treated with 2,500 mcg of vit A developed a significantly decreased response to Mch when compared to allergic 
untreated controls. Values are expressed as mean ± SEM (n = 6 mice per group) for each Mch dose point. * p < 0,05.Nutrition & Metabolism 2009, 6:44 http://www.nutritionandmetabolism.com/content/6/1/44
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duction through alterations of sCD23, sCD54 and IL-6
production [36]. And mechanisms of strengthen humoral
immunity by promoting CpG-mediated stimulation of
CD27(+) B cells via activation of p38MAPK have been
suggested [37]. Maybe, as Gottesman et al have postu-
lated, in vitro data are individually important but the met-
abolic pathways are important also in vivo, since the
situation in vitro does not reproduce the complexity of
normal physiology in vivo and, in particular, the known
plasticity in retinoid transport pathways [33].
We have also shown that retinoic acid up-regulates airway
eosinophils. Some authors have compared the effect of a
treatment with intraperitoneal injections with liposoma-
lly encapsulated retinoic acid in a mouse model of oval-
bumin. They show exacerbation of allergic immune and
inflammatory responses, most likely by promoting Th2
development [38]. Very recently, some authors have
shown that Vitamin A deficiency (VAD) can produce a
Th1 bias, whereas high-level dietary vitamin A can pro-
mote a Th2 bias using an OVA exposure mouse model.
VAD reduced serum IgE and IgG1 responses, pulmonary
eosinophilia, and the levels of IL-4 and IL-5 in BALF spec-
imen [39]. Same authors also showed that it was a differ-
ent result comparing sub-total and total deficiency of VA
[39]. Possibly, in times of inadequate vitamin A intake,
retinol binding protein RBP ensures the retinol is availa-
ble for maintaining normal cellular functions [33]. How-
ever, in cultures of normal human bone marrow, ATRA
selectively suppressed eosinophil differentiation. Simi-
larly, ATRA inhibited eosinophil/basophil differentiation
of cord blood CD34+ cells, while neutrophil differentia-
tion proceeded without impediment [40].
Surprisingly, when the highest dose of RA was applied,
percentage of eosinophil was reduced. In concordance
with results of airway eosinophilia, levels of IL-5 expres-
sion in parenchyma cells and lung function were also
abolished by treatment with highest doses of retinoic acid.
It might be explained either by an immunosuppressive
effect as postulated by others since retinoic acid seems to
down-regulate expression of the cutaneous lymphocyte-
associated antigen (CLA), a surface glycoprotein expressed
by skin-homing T cells [41]. In a very recent study, Schus-
ter et al. showed that IL-5 was significantly decreased after
high dose of vitamin A in mice, which were not fully defi-
cient in that vitamin [39]. All these results might demon-
strate that in studies with fat-soluble vitamins results of in
vitro tests should be taken carefully.
However, those levels are very difficult to get in human
beings since blood levels of retinol bound to RBP are
maintained between narrow limits throughout adult life,
and change only in response to extremes of vitamin A
shortfall and in disease states [33]. However, these results
may have some positive application as some agonist of
retinoid or antagonist of retinoid receptors might have the
ability of prevent eosinophil influx in vivo [35].
In summary, although a supplementation for infants and
young children is recommended by WHO for countries
with a high prevalence of vitamin A deficiency, that sup-
plementation with vitamin A or other retinoids have the
ability of exacerbating the Th2 response, mainly at the
time of neonatal immunization [42]. Although in our
experiments levels of IFN-gamma were unaffected by
treatment with retinoic acid [34], it has been demon-
strated that retinoic acid have some influence in Th1 to
Th2 balance. As respiratory allergic diseases are character-
ized by a late-phase immune response in which, Th2 cells
recognizing common airborne antigens produce an
inflammatory response with some Th2 cytokines IL-4, IL-
5, and IL-13, this extra-supplementation in westernised
countries might influence the allergy epidemic. The prop-
erties of retinoic acid in higher doses could be of thera-
peutic use, but more studies are still necessary.
Abbreviations
APC: Antigen presenting cells; DAB: 3.3 diamino benzi-
dine tetrahydrochlorhide; BALF: bronchoalveolar lavage
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RT-PCR of IL-5 Figure 6
RT-PCR of IL-5. For qualitative assessment, the PCR prod-
ucts were analyzed on 5% acrylamide gels stained with ethid-
ium bromide. For quantitative analysis of IL-5, we used the 
Light Cycler quantitative PCR system. Based on the standard 
values of the control samples, the relative value for each test 
sample was determined with the Light Cycler software. In 
line 1 controls. In lines 2 & 3 treated allergic mice. In lines 4 
& 5 non-treated allergic mice.Nutrition & Metabolism 2009, 6:44 http://www.nutritionandmetabolism.com/content/6/1/44
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